About Soligenix, Inc
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase 3 clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase 3 clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which is in Phase 1/2 clinical trial for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn’s disease and acute radiation enteritis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials; SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; and ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. Address: 29 Emmons Drive, Princeton, NJ, United States, 08540
Soligenix, Inc News and around…
Latest news about Soligenix, Inc (SNGX) common stock and company :
Gainers Aptevo Therapeutics Inc. (NASDAQ: APVO) shares jumped 162.8% to close at $17.03 after the company announced a clinical ...
Gainers Pasithea Therapeutics Corp. (NASDAQ: KTTA) shares jumped 216.6% to $7.00 after the company announced its subsidiary ...
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 201% to $4.00 in pre-market trading. The company filed proxy statement ...
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update RiVax® Demonstrates Durable Immunity in Mouse Model On November 4, 2021, Soligenix, Inc. (NASDAQ:SNGX) announced the publication of preclinical studies for RiVax®, the company’s heat stable ricin toxin vaccine) that showed durable protection for at least 12 months following immunization ( Novak et al., 2021 ).
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2021.
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has been granted a Pediatric Investigation Plan (PIP) product-specific waiver from the Medicines and Healthcare products Regulatory Agency (MHRA) for HyBryte™ (SGX301 or synthetic hypericin), which has successfully concluded a Phase 3 pivotal clinical study for the
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for RiVax® (heat stable ricin toxin vaccine) demonstrating enduring protection for at least 12 months post-vaccination. The article titled "Durable Immunity to Ricin Toxin Elicited by a Thermostable, Lyophilized Subunit Vac
In an SEC filing,Soligenix Inc(NASDAQ:SNGX) disclosed that it cannot file its HyBryte marketing application in the ...
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Oreola Donini, PhD, Chief Scientific Officer, will be presenting key data from the Company's thermostable vaccine technology platform, including results from the Company's programs for ricin toxin vaccine (RiVax®), COVID-19 vaccine (CiVax™) and filovirus vaccines (targ
Gainers DBV Technologies S.A. (NASDAQ: DBVT) rose 20.3% to $3.68 in pre-market trading after declining 15% on Thursday. DBV ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's the last day of the trading week and we're starting it with a dive into the biggest pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market ...
Dr. Chris Schaber Discusses Soligenix HyBryte(TM) and Thermostabilized Vaccines New York, New York--(Newsfile Corp. - October 13, 2021) - PCG Digital -- In a recent interview with Kristen Kluska, a biotechnology analyst at Cantor, Dr. Chris Schaber, President and CEO of Soligenix (NASDAQ: SNGX), spoke about the latest developments with their synthetic hypericin topical treatment HyBryte™ and the Company's ongoing research and development of thermostabilized vaccine candidates for filoviruses and
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today their poster abstract was selected as a "top abstract winner" and has been accepted for display and presentation at the 2021 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit to be held virtually on October 18-19, 2021. Ch
Gainers eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) rose 25.5% to $14.41 in pre-market trading after the company, in collaboration ...
COVID-19 Vaccine Candidate Demonstrates Broad Neutralizing Antibody Response Against Beta, Gamma and Delta Variants New York, New York--(Newsfile Corp. - October 7, 2021) - PCG Digital -- Shipping and administering COVID-19 vaccines that need to be stored at sub-zero temperatures is hampering the pandemic recovery efforts of health professionals around the world. Soligenix, Inc (NASDAQ: SNGX), a US-based late-stage biopharmaceutical company, is developing a solution to that problem. The Company
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update CiVax™ Shows Protective Effects Against SARS-CoV-2 Variant in NHP On September 28, 2021, Soligenix, Inc. (NASDAQ:SNGX) announced the publication of pre-clinical immunogenicity studies for CiVax™, the company’s heat-stable COVID-19 vaccine candidate ( To et al., 2021 ). CiVax™ is composed of a recombinant pre-fusion
Gainers Geovax Labs (NASDAQ:GOVX) shares rose 46.37% to $6.06 during Tuesday's after-market session. This security traded at a ...
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for CiVax™ (heat stable COVID-19 vaccine program) demonstrating durable broad-spectrum neutralizing antibody responses, including against the Beta, Gamma and Delta variants of concern. The article, titled "Protein Vaccine I
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will participate in a fireside chat hosted by Kristen Kluska, Director, Equity Research, at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 29, 2021 at 8:00AM ET. In addi
Soligenix Inc(NASDAQ: SNGX) says that following the validation of synthetic hypericin's biologic activity, the Company will ...
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that following the validation of synthetic hypericin's biologic activity in the positive pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study in cutaneous T-cell lymphoma (CTCL), as well as positive proof-of-concept (PoC) demonstrated in a small Pha
Gainers aTyr Pharma (NASDAQ:LIFE) stock increased by 13.77% to $10.41 during Monday's after-market session. Trading volume for this ...
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
TheFDA has granted orphan drug designationto the active ingredient hypericin to treat T-cell lymphoma, extending the ...
Gainers Soligenix (NASDAQ:SNGX) stock increased by 22.85% to $1.29 during Thursday's pre-market session. The ...
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Office of Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient hypericin for the treatment of T-cell lymphoma, extending the target population beyond cutaneous T-cell
Soligenix, Inc (SNGX) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
